Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
University of Washington
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Ohio State University Comprehensive Cancer Center
Celgene
Mayo Clinic
Eli Lilly and Company
City of Hope Medical Center
Dana-Farber Cancer Institute
Medical College of Wisconsin
CStone Pharmaceuticals
The University of Texas Health Science Center at San Antonio
Northwestern University
Guangzhou Lupeng Pharmaceutical Company LTD.
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Dana-Farber Cancer Institute
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Therapeutic Advances in Childhood Leukemia Consortium
Fred Hutchinson Cancer Center
University of Virginia
University of Washington
Fate Therapeutics
SWOG Cancer Research Network
Weill Medical College of Cornell University
Tianjin Medical University Cancer Institute and Hospital
ADC Therapeutics S.A.
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
University of Washington
Celgene
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
University of Utah
UNC Lineberger Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Seagen Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
University of California, San Francisco